Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BBSRC awards cutting-edge biomedical equipment to Oxford

General

BBSRC is investing £10m in 20 advanced scientific research instruments.

BBSRC is investing £10m in 20 advanced scientific research instruments under the Advanced Life Sciences Research Technology initiative (ALERT 13) to help keep the UK at the forefront of biological sciences research. Shankar Srinivas and Paul Riley from the Department of Physiology, Anatomy and Genetics, together with Ilan Davis (Biochemistry and Micron Oxford Advanced Bioimaging Unit), Jordan Raff (Sir William Dunn School of Pathology) and Roger Patient (Weatherall Institute of Molecular Medicine) have been awarded one of the UK’s first two commercial Fluorescence Light Sheet Microscopes to probe cell and tissue dynamics, worth just under £500k. This instrument will allow groups from Oxford and further afield to examine dynamic process within living cells in exquisite detail, enabling exciting advances in a broad range of areas in cell, developmental and stem cell biology.

Read more

Similar stories

Tamoxifen repurposing study shows no benefit in treating deadly fungal meningitis

Hopes that tamoxifen could improve survival for a deadly form of fungal meningitis have been dashed by the results of a clinical trial conducted by University of Oxford researchers and published today in eLife.

Oxford researchers awarded funding to complete community COVID-19 antiviral trial

Researchers from the Nuffield Department of Primary Care Health Sciences, University of Oxford, have today announced that they have been awarded funding through the National Institute for Health Research (NIHR) to work with several UK universities and carry out a first-of-its-kind clinical trial, testing novel antiviral COVID-19 treatments for use early on in the illness by people in the community with COVID-19 who are at higher risk of complications.

New therapeutic targets identified to treat inflammatory bowel disease

Millions of patients with ulcerative colitis or Crohn’s disease, collectively known as inflammatory bowel disease (IBD), are given fresh hope as a new study shows why some of them do not respond to current treatments.

Oxford researchers call for an urgent re-evaluation of “weak” opioid safety profile

A new study associates dispensation doses of tramadol with increased risk of mortality, cardiovascular events, and fractures compared to the use of codeine to treat pain.

Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age

A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.

Drug could help diabetic hearts recover after heart attack - Oxford research

Researchers at the University of Oxford have identified a drug that could ultimately help improve heart function in people with diabetes who have heart attacks.